BigThink Breast Cancer Treatment 'Neorings' Surpasses 5 Billion KRW in Cumulative Sales One Year After Prescription

BigThink Therapeutics, a bio-subsidiary of KPS, is showing steady growth based on strong performance. This is due to the increasing number of prescriptions for its first marketed drug, Neurings Tab (active ingredient: Neratinib Maleate).

According to KPS on the 19th, the sales revenue of the breast cancer drug Neurings Tab for the first half of this year (January to June) has exceeded 2.7 billion KRW. This significantly surpasses last year's total annual sales of 2.49 billion KRW, the first year of sales, with a growth rate of more than double compared to the same period last year. Sales for this year are expected to exceed 5 billion KRW.

Since its approval, Neurings Tab has passed the Drug Committee (DC) at over 50 hospitals nationwide, including the Big 5 general hospitals such as Seoul National University Hospital, Asan Medical Center, Samsung Seoul Hospital, Severance Hospital, and Seoul St. Mary's Hospital, and is currently prescribed at more than 30 hospitals. The expected sales revenue for this year is projected to increase by at least 120% compared to the previous year.

Neurings Tab is an oral treatment for HER2-positive breast cancer developed by the U.S. company Puma Biotechnology. BigThink introduced it to Korea and received approval from the Ministry of Food and Drug Safety in October 2021.

The approved indication is as an adjuvant therapy after surgery for early breast cancer patients who are HER2 receptor-positive and hormone receptor-positive. It is the only anticancer treatment option that can reduce the risk of recurrence and brain metastasis in patients treated with trastuzumab (product name Herceptin)-based therapy. Notably, it is recommended as an early breast cancer treatment in the clinical guidelines of the Korean Breast Cancer Society and the National Comprehensive Cancer Network (NCCN) in the United States.

BigThink is also pursuing business diversification through the introduction of overseas pharmaceuticals.

Kim Ha-yong, CEO of BigThink Therapeutics, stated, "Following Neurings, we have also secured Asian distribution rights for the topical solution for managing oral mucositis in cancer patients, MUCOSAMIN®, and have begun full-scale sales. We will strive to achieve annual sales of 10 billion KRW."